ProQR Therapeutics (PRQR) FCF Margin (2013 - 2026)
ProQR Therapeutics (PRQR) posted quarterly FCF Margin of 572.01% for Q1 2026, down 20467.0% year-on-year from N/an in Q1 2025, and down 60.89% on a QoQ basis from 355.52% in Q4 2025.
ProQR Therapeutics (PRQR) FCF Margin (2013 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported FCF Margin for 14 consecutive years, with 572.01% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin fell 20467.0% year-over-year to 572.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 390.54% (down 15948.0% YoY) and the FY2025 annual result came in at 349.6%, down 13543.0% from the prior year.
- FCF Margin retreated to 572.01% in Q1 2026 per PRQR's latest filing, from 355.52% in the prior quarter.
- Over the last five years, FCF Margin for PRQR reached as high as 6821.53% in Q1 2023 and fell as low as 2675.28% in Q4 2022.
- A 5-year average of 336.23% and a median of 367.34% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 865436 bps — and 2024, when it plunged 714512 bps.
- Year by year, FCF Margin stood at 2675.28% in 2022, then jumped by 93 bps to 173.93% in 2023, then slumped by 97 bps to 341.98% in 2024, then decreased by 4 bps to 355.52% in 2025, then plunged by 61 bps to 572.01% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 572.01%, 355.52%, and 418.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - | -572.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -572.01% |
| Dec 31, 2025 | -355.52% |
| Sep 30, 2025 | -418.67% |
| Jun 30, 2025 | -315.67% |
| Mar 31, 2025 | -367.34% |
| Dec 31, 2024 | -341.98% |
| Sep 30, 2024 | -139.76% |
| Jun 30, 2024 | -113.28% |
| Mar 31, 2024 | -323.60% |
| Dec 31, 2023 | -173.93% |
| Sep 30, 2023 | -587.88% |
| Jun 30, 2023 | -891.12% |
| Mar 31, 2023 | 6,821.53% |
| Dec 31, 2022 | -2,675.28% |
| Sep 30, 2022 | -1,857.25% |
| Jun 30, 2022 | -1,571.29% |
| Mar 31, 2022 | -1,832.83% |
| Dec 31, 2021 | 1,910.88% |
| Sep 30, 2021 | -903.90% |
| Jun 30, 2021 | -4,085.19% |